Nova Vascular LLC dba NOVARX
Has NOVARX received an FDA warning letter? Yes. FDA issued a warning letter dated June 8, 2026 concerning products containing semaglutide and tirzepatide.
Letter facts
- Letter date
- June 8, 2026 (2026-06-08)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Telehealth
- Products named
- compounded semaglutide productscompounded tirzepatide products
- Violation categories
- MisbrandingFalse or misleading claims
Understanding these violation categories
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
False or misleading claims
FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.
Factual Violation Summary
FDA found NOVARX's website made false or misleading claims for compounded semaglutide and tirzepatide, including labeling NOVA RX as compounder, implying FDA approval, and calling source pharmacies FDA-approved.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- misbranding under FD&C Act sections 502(a) and 502(bb)
- false or misleading labeling and advertising
- prohibited act under section 301(a) (interstate commerce of misbranded drugs)
More letters about Semaglutide
Recent FDA warning letters concerning Semaglutide:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Similar violations (Misbranding)
Recent warning letters with related regulatory findings:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.